Immutep (IMMP) said Monday that a phase 2b trial evaluating eftilagimod alfa in combination with Merck's (MRK) Keytruda to treat head and neck squamous cell cancer produced an "excellent" median overall survival result of 17.6 months.
The firm said the result "compares favorably" with to historical results from the two current standard-of-care approaches, while the drug combination was well-tolerated with no new safety signals.
Immutep said it has requested a meeting with the US Food and Drug Administration to discuss next steps including potential paths to approval.
Immutep shares rose nearly 13% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。